AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KAUG 172 min read$NXGL

NEXGEL, INC. (NXGL): Results of Operations and Financial Condition

NEXGEL, INC. (NXGL) filed an SEC Form 8-K — Results of Operations and Financial Condition. false 0001468929 0001468929 2026-08-17 2026-08-17 0001468929 NXGL:CommonStockParValue0.001Member 2026-08-17 2026-08-17 0001468929 NXGL:WarrantsToPurchaseCommonStockMember 2026-08-17 2026-08-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE

Original reporting
SEC EDGAR 8-K
Published Aug 17, 2026, 12:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 12:37 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$NXGL
Neutral
low confidence
Mentioned
$NXGL
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NXGLNeutralLow
01

Why it matters

The filing itself is a procedural disclosure that becomes tradable once Exhibit 99.1 financials and any updates are reviewed; the excerpt does not provide those figures.

02

Market read

This is a quarterly results disclosure event for NXGL, but the excerpt contains no financial data to quantify upside or downside.

03

What to watch

Traders should focus on Exhibit 99.1 details (revenue, gross margin, cash burn, liquidity, and any forward guidance) since those are not present in the scraped body.

Relevance 7/10Novelty 2/10Timing: filed Aug 17, 2026 premarket/early session with results press release attached

Background

The company submitted SEC Form 8-K under Item 2.02, stating it issued a press release with results for the quarter ended June 30, 2026 and other corporate updates.

Company-level read

Ticker impact

$NXGLNeutralLow confidence
Context

NexGel filed an 8-K furnishing its quarter ended June 30, 2026 results via Exhibit 99.1, making NXGL the filing’s subject.

Expected impact

Near-term price reaction is possible once traders read Exhibit 99.1, but this text alone provides no numbers to forecast direction.

Evidence & confidence

The filing states a press release was issued and attached, yet the provided content omits the quarter’s reported metrics, so the incremental trading information cannot be assessed from the excerpt.

Market effects

Sector

No sector read-through is provided in the excerpt beyond routine quarterly reporting.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the excerpt lacks the actual results, the market may already be positioned for the release, making any reaction more about the specific numbers and outlook than the existence of the filing.

Key entities

  • issuer
    NexGel, Inc.

    Subject of the 8-K filing, reporting quarter ended June 30, 2026 results via attached Exhibit 99.1.

  • executive
    Ian Blackman

    CFO signing the 8-K.

Read at source← All news

Related articles

AUG 17
$LONAMed

LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances

LeonaBio (NASDAQ:LONA) reported a Q2 loss of $0.80 per share, smaller than analysts’ $1.12 forecast. Net loss rose to $19.0 million from $7.0 million a year earlier. Phase 3 ELAINE-3 enrollment nears 600 target, with 495 patients enrolled and topline results expected in H2 2027. Cash fell to $51.1 million from $88.3 million.

yahoo.com4 min
AUG 17
$JSPRMed

Jasper Therapeutics beats Q2 expectations but shares fall after results

Jasper Therapeutics (NASDAQ:JSPR) reported Q2 2026 adjusted loss of $0.10 per share, better than the $0.28 consensus, and a net loss of $2.8 million. Shares fell 4.24% pre-market. In July, Jasper completed an all-stock acquisition of Kira Pharmaceuticals and a $132 million private placement, extending its funding runway into 2H 2028. Pipeline updates include KP-104 Phase 2 interim data in Q4 2026 and briquilimab and KP-701 milestones in early 2027.

yahoo.com4 min
AUG 17
$PPSIMed

PIONEER POWER SOLUTIONS, INC. (PPSI): Results of Operations and Financial Condition

PIONEER POWER SOLUTIONS, INC. (PPSI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Pioneer Power Announces Financial Results for Second Quarter 2026 and Provides a Business Update ● Backlog Grew 32% Sequentially to $18.4 Million ● Projecting Revenue of Approximately $15 Million in Second Half of 2026, Representing More

SEC EDGAR 8-K6 min
AUG 17
$BDCOMed

BLUE DOLPHIN ENERGY CO (BDCO): Results of Operations and Financial Condition

BLUE DOLPHIN ENERGY CO (BDCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_967513.htm EXHIBIT 99.1 BDCO EARNINGS RLS DATED AUGUST 17, 2026 ex_967513.htm Exhibit 99.1 PRESS RELEASE FOR IMMEDIATE RELEASE BLUE DOLPHIN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS ● Total gross profit of $25.1 million and $45.7 million for the three and six mon

SEC EDGAR 8-K4 min